CTOs on the Move

Palvella Therapeutics

www.palvellatx.com

 
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Palvella Therapeutics raised $25M on 05/28/2020

Similar Companies

Healthtech Holdings

HealthTech Holdings Inc. is a health information technology holding company that owns Healthcare Management Systems, MEDHOST and Sentry Healthcare Services.

Tranquis Therapeutics

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.

Mobilion Systems

MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery.

HONOUR

HONOUR is a global leader in chemistry-driven solutions, focusing on the pharmaceutical, electronics, and performance materials industries. The company emphasizes innovation and agility, supported by a strong scientific workforce. HONOUR specializes in Custom Synthesis and Contract Development and Manufacturing Organization (CDMO) services, offering a range of customizable chemicals and ingredients, including coupling reagents, excipients, and polymer monomers. The Research & Development team at HONOUR combines advanced chemistry and technology to create practical solutions tailored to the unique needs of its partners. The company values trust and integrity in its relationships, aiming to foster sustainable progress in collaboration with its clients. HONOUR serves a diverse clientele, including pharmaceutical companies and electronics manufacturers, providing them with expert R&D capabilities and customized chemical solutions.

STIMIT

STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.